From the Journals

Psoriasis not consistently linked to adverse pregnancy outcomes


 

Psoriasis was not consistently associated with adverse pregnancy outcomes across nine studies in a systematic review of the literature, but four of the studies reported significant increases in at least one adverse outcome among women with psoriasis, according to a report in the British Journal of Dermatology.

Many women with psoriasis develop the disorder during their reproductive years, and more than 100,000 births to such patients are estimated to occur in the United States each year. Other autoimmune diseases are known to adversely affect pregnancy outcomes, but the issue has not been well studied among women with psoriasis, said Robert Bobotsis, a medical student at Western University, London (Ont.), and his associates.

They performed a systematic review of the literature to examine a possible link, but were only able to find nine fair- or good-quality studies involving a total of 4,756 pregnancies from which to extract data concerning a possible association. This small sample size may have been underpowered to detect the uncommon adverse pregnancy outcomes being assessed. Moreover, the investigators were unable to conduct a meta-analysis pooling the data because the effect measures were inconsistent across the nine studies, Mr. Bobotsis and his associates noted.

The review included a retrospective case series, a retrospective case control study, three retrospective cohort studies, two prospective cohort studies, one cross-sectional study, and one study combining prospective and retrospective cohorts. It “did not demonstrate an increased risk of poor outcomes in pregnant women with psoriasis” (Br J Dermatol. 2016 Jul 24;175:464-72).

However, four studies showed that compared with women who didn’t have psoriasis, those who did were at significantly increased risk for spontaneous abortion, cesarean delivery, low birth weight, macrosomia, large for gestational age, and prematurity, with odds ratios as high as 5.6. “Our results should be viewed as an opportunity to further research pregnancy outcomes in psoriasis,” the investigators said.

Recommended Reading

FDA advisory panel unanimously backs biosimilars for Humira, Enbrel
MDedge Rheumatology
Brodalumab approval recommended, despite possible suicide signal
MDedge Rheumatology
Psoriatic arthritis patients face more endocrine comorbidities
MDedge Rheumatology
SHARE initiative releases consensus-based JDM management recommendations
MDedge Rheumatology
Psoriasis cardiovascular risk parallels type 2 diabetes
MDedge Rheumatology
Ixekizumab improved psoriatic arthritis in patients who had not taken biologics
MDedge Rheumatology
Biosimilar version of etanercept gains FDA approval
MDedge Rheumatology
Tips on how to differentiate CLE from dermatomyositis
MDedge Rheumatology
Be alert for dermatomyositis without muscle disease
MDedge Rheumatology
FDA approves biosimilar adalimumab
MDedge Rheumatology